Repare Therapeutics (RPTX) has released an update.
Repare Therapeutics, a precision oncology company, has reported its Q2 2024 financial results while progressing with clinical trials, including the MYTHIC trial for ovarian and endometrial cancers. The FDA granted Fast Track designation for their drug lunresertib, and initial Phase 1 data for gastrointestinal cancer treatment was positively received. The company is also preparing for a potential registrational trial in 2025, and welcomed Dr. Steven H. Stein to their Board of Directors.
For further insights into RPTX stock, check out TipRanks’ Stock Analysis page.
